Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Humans Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

NCT05868382
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, mRNA-1010.4, mRNA-1010.6
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

NCT00953524
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA), Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
15
States / cities
Hoover, Alabama • Chandler, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions

NCT00865462
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of KSP Heptapeptide (KSP-910638G)

NCT03161418
View directory record Official record
Conditions
Healthy Adults
Interventions
KSP-910638G, 0.4 mg, KSP-910638G, 1.2 mg
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

NCT00366782
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rB/HPIV3, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scavenging of Reactive Carbonyl Species by Apple Polyphenols in Human

NCT03911050
View directory record Official record
Conditions
Human Health, Polyphenols, Pharmacokinetics
Interventions
Apple consumption, Control group
Dietary Supplement
Lead sponsor
North Carolina Agriculture & Technical State University
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

NCT05328726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GZR-18, Placebo
Drug · Other
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study of Adults With Autism Spectrum Disorders

NCT01093768
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Oxytocin, Vasopressin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

NCT03636204
View directory record Official record
Conditions
Healthy, Frontotemporal Dementia
Interventions
AL001, Placebo
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

NCT02539576
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
ABC/DTG/3TC FDC tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 26, 2026, 6:57 PM EDT
Completed No phase listed Observational

PET Imaging of Nicotinic Acetylcholine Receptors

NCT01046513
View directory record Official record
Conditions
Healthy Volunteers, Nicotine Dependence, Pharmacokinetics
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

NCT01209117
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus
Interventions
GSK2248761 WBM Capsule, GSK2248761 WBM Tablet Formulation 1, GSK2248761 WBM Tablet Formulation 2, GSK2248761 WBM Tablet Formulation 3, GSK2248761 WBM Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cranberry Enhances Human Immune Function and Reduces Illness

NCT01398150
View directory record Official record
Conditions
Healthy Humans
Interventions
Beverage made to look like the cranberry beverage, Beverage made from cranberry compounds
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

NCT00368238
View directory record Official record
Conditions
Healthy Subjects
Interventions
Recombinant human erythropoietin alfa (drug), Aspirin (drug), Clopidogrel (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 40 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2006 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

NCT01802918
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 26, 2026, 6:57 PM EDT
Completed No phase listed Observational

Blood Vessel Study

NCT01524549
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

NCT00833378
View directory record Official record
Conditions
Hepatitis C
Interventions
Eltrombopag, Lopinavir/Ritonavir, Eltrombopag and Lopinavir/Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

NCT01596725
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Norwalk Vaccine Study

NCT00973284
View directory record Official record
Conditions
Acute Gastroenteritis, Norwalk Virus Infection
Interventions
Norwalk VLP vaccine, mannitol and sucrose, Norwalk virus
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction (DDI) Rifabutin

NCT02138084
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Rifabutin, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine

NCT01545349
View directory record Official record
Conditions
Healthy, Influenza
Interventions
Lactobacillus rhamnosus GG ATCC 53103 (LGG), Placebo, Live attenuated influenza vaccine
Biological
Lead sponsor
Patricia L. Hibberd
Other
Eligibility
65 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 26, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 26, 2026, 6:57 PM EDT